RT Journal Article
SR Electronic
T1 Coronavirus Disease (COVID-19) Pandemic: An Overview of Systematic Reviews
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.16.20068213
DO 10.1101/2020.04.16.20068213
A1 do Nascimento, Israel Júnior Borges
A1 O’Mathúna, Dónal P.
A1 von Groote, Thilo Caspar
A1 Abdulazeem, Hebatullah Mohamed
A1 Weerasekara, Ishanka
A1 Marusic, Ana
A1 Puljak, Livia
A1 Civile, Vinicius Tassoni
A1 Zakarija-Grkovic, Irena
A1 Pericic, Tina Poklepovic
A1 Atallah, Alvaro Nagib
A1 Filoso, Santino
A1 Bragazzi, Nicola Luigi
A1 Marcolino, Milena Soriano
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/04/22/2020.04.16.20068213.abstract
AB Background Navigating the rapidly growing body of scientific literature on the SARS-CoV-2 pandemic is challenging and ongoing critical appraisal of this output is essential. We aimed to collate and summarize all published systematic reviews on the coronavirus disease (COVID-19).Methods Nine databases (Medline, EMBASE, Cochrane Library, CINAHL, Web of Sciences, PDQ-Evidence, WHO’s Global Research, LILACS and Epistemonikos) were searched from December 1, 2019 to March 24, 2020. Systematic reviews analyzing primary studies of COVID-19 were included. Two authors independently undertook screening, selection, extraction (data on clinical symptoms, prevalence, pharmacological and non-pharmacological interventions, diagnostic test assessment, laboratory and radiological findings) and quality assessment (AMSTAR 2). Meta-analysis on prevalence of clinical outcomes was performed.Results Eighteen systematic reviews were included; one was empty. Using AMSTAR 2, confidence in the results of 13 reviews was rated as “critically low”, one as “low”, one as “moderate” and two as “high”. Symptoms of COVID-19 were (range values of point estimates): fever (82–95%), cough with or without sputum (58–72%), dyspnea (26–59%), myalgia or muscle fatigue (29–51%), sore throat (10–13%), headache (8– 12%) and gastrointestinal complaints (5–9%). Severe symptoms were more common in men. Elevated C-reactive protein (associated with lymphocytopenia) and lactate dehydrogenase, and slightly elevated aspartate and alanine aminotransferase, were commonly described. Thrombocytopenia and elevated levels of procalcitonin and cardiac troponin I were associated with severe disease. Chest imaging described a frequent pattern of uni- or bilateral multilobar ground-glass opacity. Only one review investigated the impact of medication (chloroquine) but found no verifiable clinical data. All-cause mortality ranged from 0.3% to 14%.Conclusions Confidence in the results of most reviews was “critically low”. Future studies and systematic reviews should adhere to established methodologies. The majority of included systematic reviews were hampered by imprecise search strategy and no previous protocol submission.Protocol registration This is an extension of a PROSPERO protocol (CRD42020170623); protocol available on Open Science Framework (https://osf.io/6xtyw).Competing Interest StatementThe authors have declared no competing interest.Funding StatementAuthors declare no external funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data involved in this submission is fully available.